A Primer on Foreign Corrupt Practices Act and Anti-Corruption Issues for Healthcare and Life Science Companies, Part I: FCPA and Anti-Corruption 101 for Healthcare and Life Science Companies 

Wednesday, May 11, 2011
This webinar series is brought to you by the Fraud and Abuse Practice Group, and is co-sponsored by the Healthcare Liability and Litigation (HL&L), Hospitals and Health Systems (HHS), Life Sciences, and Teaching Hospitals and Academic Medical Centers (TH/AMC) Practice Groups

Description

Part I of this series will focus on the following topics:

• Overview of the Foreign Corrupt Practices Act (FCPA) Statute
• Understanding how the FCPA applies to healthcare and life science companies
• Update on current FCPA enforcement initiatives
• Major FCPA risks for healthcare and life science companies
• Overseas clinical research
• Product sales
• Payments to government-employed healthcare providers and hospital committees
• Third parties
• Gifts, entertainment, travel, and hospitality
• Facilitating Payments Exception
• Control Person Liability
• Adequate accounting and internal controls
• Doing business in high-risk jurisdictions
• Overview of the UK Bribery Act and its impact on healthcare and life science companies—“there’s a new sheriff in town”

Learn more about Part II or Part III.

Presenters

• John "Jay" S. Darden, Esquire
  Partner
  Patton Boggs LLP, Washington, DC
  
  
• John E. Kelly, Esquire
  Partner
  Fulbright & Jaworski LLP, Washington, DC

Moderator

• Carol A. Poindexter, Esquire
  Partner
  Shook Hardy & Bacon LLP, Washington, DC, and Kansas City, MO